Srijan Sen, M.D., Ph.D.
doi : 10.1056/NEJMp2209540
Vol. 387 No. 18
Troyen Brennan, M.D., M.P.H.
doi : 10.1056/NEJMp2210637
Kari Nadeau, M.D., Ph.D., Frederica Perera, Dr.P.H., Ph.D., Renee N. Salas, M.D., M.P.H., and Caren G. Solomon, M.D., M.P.H.
doi : 10.1056/NEJMp2213408
Guy M. Goodwin, F.Med.Sci., Scott T. Aaronson, M.D., Oscar Alvarez, M.R.C.Psych., Peter C. Arden, M.P.H., Annie Baker, R.G.N., James C. Bennett, M.Sc., Catherine Bird, M.Sc., Renske E. Blom, M.D., Christine Brennan, M.Sc., Donna Brusch, C.C.R.C., Lisa Burke, M.Sc., Kete Campbell-Coker, R.G.N.,
doi : 10.1056/NEJMoa2206443
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.
Sharon M. Castellino, M.D., Qinglin Pei, Ph.D., Susan K. Parsons, M.D., David Hodgson, M.D., Kathleen McCarten, M.D., Terzah Horton, M.D., Ph.D., Steve Cho, M.D., Yue Wu, M.S., Angela Punnett, M.D., Hema Dave, M.D., Tara O. Henderson, M.D., Bradford S. Hoppe, M.D.,
doi : 10.1056/NEJMoa2206660
In adults with advanced-stage Hodgkin’s lymphoma, the CD30-directed antibody–drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy, but also more toxic effects, than chemotherapy alone. The efficacy of this targeted therapy approach in children and adolescents with Hodgkin’s lymphoma is unclear.
Frank H. Bloomfield, Ph.D., Yannan Jiang, Ph.D., Jane E. Harding, D.Phil., Caroline A. Crowther, M.D., and Barbara E. Cormack, Ph.D. for the ProVIDe Trial Group*
doi : 10.1056/NEJMoa2204886
Whether higher parenteral amino acid intake improves outcomes in infants with extremely low birth weight is unclear.
Evan J. Anderson, M.D., C. Buddy Creech, M.D., M.P.H., Vladimir Berthaud, M.D., M.P.H., Arin Piramzadian, D.O., Kimball A. Johnson, M.D., Marcus Zervos, M.D., Fredric Garner, M.D., Carl Griffin, M.D., Khozema Palanpurwala, M.D., Mark Turner, M.D., Jeffrey Gerber, M.D., Ph.D., Richard L. Bennett, M.D.,
doi : 10.1056/NEJMoa2209367
The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown.
Laveena Munshi, M.D., Jordi Mancebo, M.D., and Laurent J. Brochard, M.D.
doi : 10.1056/NEJMra2204556
Quentin Binet, M.D., and Ivan Borbath, M.D., Ph.D.
doi : 10.1056/NEJMicm2203797
Tun H. Lui, F.H.K.A.M. (Ortho. Surg.), and Amanda M.Y. Slocum, F.H.K.A.M. (Ortho. Surg.)
doi : 10.1056/NEJMicm2202238
Marla Lipsyc-Sharf, M.D., Nathan T. Connell, M.D., M.P.H., John W. Ostrominski, M.D., Bruce D. Levy, M.D., and Joseph Loscalzo, M.D., Ph.D.
doi : 10.1056/NEJMcps2115778
Mark Roschewski, M.D., and Catherine M. Bollard, M.B., Ch.B., M.D.
doi : 10.1056/NEJMe2211587
Camilia R. Martin, M.D.
doi : 10.1056/NEJMe2212522
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., C. Corey Hardin, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2214245
doi : 10.1056/NEJMc2211055
doi : 10.1056/NEJMc2212585
doi : 10.1056/NEJMx220009
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟